Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data

Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) is an efficient biomarker specific for hepatocellular carcinoma (HCC). Some researchers have proved that levels of PIVKA-II reflect HCC oncogenesis and progression. However, the effectiveness of PIVKA-II based on real-world clnical dat...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2017-09, Vol.17 (1), p.608-608, Article 608
Main Authors: Yu, Rentao, Tan, Zhaoxia, Xiang, Xiaomei, Dan, Yunjie, Deng, Guohong
Format: Article
Language:English
Subjects:
Adult
AFP
Aged
alpha-Fetoproteins - genetics
Benign
Biological markers
Biomarkers
Biomarkers, Tumor - genetics
Cancer therapies
Carcinoma, Hepatocellular - epidemiology
Carcinoma, Hepatocellular - genetics
Carcinoma, Hepatocellular - pathology
Cell Transformation, Neoplastic - genetics
Cell Transformation, Neoplastic - pathology
Chemiluminescence
Cirrhosis
Data processing
Development and progression
Enzyme immunoassay
Female
Gene Expression Regulation, Neoplastic - genetics
HCC
Health aspects
Hepatitis
Hepatocellular carcinoma
Hepatology
Humans
Immunoassay
Liver cancer
Liver cirrhosis
Liver Cirrhosis - epidemiology
Liver Cirrhosis - genetics
Liver Cirrhosis - pathology
Liver Neoplasms - epidemiology
Liver Neoplasms - genetics
Liver Neoplasms - pathology
Male
Medical imaging
Medical prognosis
Middle Aged
Multivariate analysis
Neoplasm Recurrence, Local - epidemiology
Neoplasm Recurrence, Local - genetics
Neoplasm Recurrence, Local - pathology
NMR
Nodules
Nuclear magnetic resonance
PIVKA-II
Protein Precursors - genetics
Proteins
Prothrombin - genetics
Real-world
Software
Statistical analysis
Studies
Surveillance
Survival analysis
Tumorigenesis
Vitamin K
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) is an efficient biomarker specific for hepatocellular carcinoma (HCC). Some researchers have proved that levels of PIVKA-II reflect HCC oncogenesis and progression. However, the effectiveness of PIVKA-II based on real-world clnical data has barely been studied. A total of 14,861 samples were tested in Southwest Hospital in over 2 years' time. Among them, 4073 samples were PIVKA-II positive. Finally, a total of 2070 patients with at least two image examinations were enrolled in this study. Levels of AFP and PIVKA-II were measured by chemiluminescence enzyme immunoassay (CLEIA) and chemiluminescent microparticle Immunoassay (CMIA), respectively. A total of 1016 patients with HCC were detected by PIVKA-II in a real-world application. In all these cases, 88.7% cases primarily occurred and patients with advanced HCC covered 61.3%. Levels of PIVKA-II were significantly higher in advanced group (4650.0 mAU/ml, 667.0-33,438.0 mAU/ml) than early-stage group (104.5 mAU/ml, 61.0-348.8 mAU/ml; P 
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-017-3609-6